HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $311,521 | +26.2% | 8,155 | +19.1% | 0.01% | +25.0% |
| Q2 2023 | $246,899 | -11.8% | 6,845 | -6.6% | 0.00% | 0.0% |
| Q1 2023 | $279,971 | -38.2% | 7,331 | -7.9% | 0.00% | -42.9% |
| Q4 2022 | $452,981 | -5.4% | 7,961 | -34.3% | 0.01% | -22.2% |
| Q3 2022 | $479,000 | -0.6% | 12,113 | +10.7% | 0.01% | 0.0% |
| Q2 2022 | $482,000 | +17.6% | 10,947 | +6.4% | 0.01% | +28.6% |
| Q1 2022 | $410,000 | -0.7% | 10,292 | +0.2% | 0.01% | 0.0% |
| Q4 2021 | $413,000 | -1.2% | 10,273 | +0.3% | 0.01% | -22.2% |
| Q3 2021 | $418,000 | +8.3% | 10,243 | +20.5% | 0.01% | +12.5% |
| Q2 2021 | $386,000 | +8.7% | 8,503 | -0.1% | 0.01% | 0.0% |
| Q1 2021 | $355,000 | -3.0% | 8,511 | -0.6% | 0.01% | -20.0% |
| Q4 2020 | $366,000 | +36500.0% | 8,561 | +34144.0% | 0.01% | – |
| Q3 2020 | $1,000 | 0.0% | 25 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 25 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |